181 related articles for article (PubMed ID: 38441386)
21. Functionalized PDA/DEX-PEI@HA nanoparticles combined with sleeping-beauty transposons for multistage targeted delivery of CRISPR/Cas9 gene.
Ma K; Li W; Zhu G; Sun S; Chi H; Yin Y; Diao H; Xing XJ; Guo Z; Wang L; Xu W; Cui C; Xu J
Biomed Pharmacother; 2021 Oct; 142():112061. PubMed ID: 34449313
[TBL] [Abstract][Full Text] [Related]
22. Integrase-Deficient Lentiviral Vector as an All-in-One Platform for Highly Efficient CRISPR/Cas9-Mediated Gene Editing.
Ortinski PI; O'Donovan B; Dong X; Kantor B
Mol Ther Methods Clin Dev; 2017 Jun; 5():153-164. PubMed ID: 28497073
[TBL] [Abstract][Full Text] [Related]
23. Mesenchymal stem cell fate following non-viral gene transfection strongly depends on the choice of delivery vector.
Gonzalez-Fernandez T; Sathy BN; Hobbs C; Cunniffe GM; McCarthy HO; Dunne NJ; Nicolosi V; O'Brien FJ; Kelly DJ
Acta Biomater; 2017 Jun; 55():226-238. PubMed ID: 28363788
[TBL] [Abstract][Full Text] [Related]
24. How Far Are Non-Viral Vectors to Come of Age and Reach Clinical Translation in Gene Therapy?
Sainz-Ramos M; Gallego I; Villate-Beitia I; Zarate J; Maldonado I; Puras G; Pedraz JL
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299164
[TBL] [Abstract][Full Text] [Related]
25. Appraisal for the Potential of Viral and Nonviral Vectors in Gene Therapy: A Review.
Butt MH; Zaman M; Ahmad A; Khan R; Mallhi TH; Hasan MM; Khan YH; Hafeez S; Massoud EES; Rahman MH; Cavalu S
Genes (Basel); 2022 Jul; 13(8):. PubMed ID: 36011281
[TBL] [Abstract][Full Text] [Related]
26. Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy.
Song X; Liu C; Wang N; Huang H; He S; Gong C; Wei Y
Adv Drug Deliv Rev; 2021 Jan; 168():158-180. PubMed ID: 32360576
[TBL] [Abstract][Full Text] [Related]
27. The research of nanoparticles as gene vector for tumor gene therapy.
Sun NF; Liu ZA; Huang WB; Tian AL; Hu SY
Crit Rev Oncol Hematol; 2014 Mar; 89(3):352-7. PubMed ID: 24210877
[TBL] [Abstract][Full Text] [Related]
28. Magnetically-assisted viral transduction (magnetofection) medical applications: An update.
Azadpour B; Aharipour N; Paryab A; Omid H; Abdollahi S; Madaah Hosseini H; Malek Khachatourian A; Toprak MS; Seifalian AM
Biomater Adv; 2023 Nov; 154():213657. PubMed ID: 37844415
[TBL] [Abstract][Full Text] [Related]
29. Production of lentiviral vectors for transducing cells from the central nervous system.
Li M; Husic N; Lin Y; Snider BJ
J Vis Exp; 2012 May; (63):e4031. PubMed ID: 22664962
[TBL] [Abstract][Full Text] [Related]
30. Cationic Solid Lipid Nanoparticles as Non Viral Vectors for the Inhibition of Hepatocellular Carcinoma Growth by RNA Interference.
Botto C; Augello G; Amore E; Emma MR; Azzolina A; Cavallaro G; Cervello M; Bondì ML
J Biomed Nanotechnol; 2018 May; 14(5):1009-1016. PubMed ID: 29883570
[TBL] [Abstract][Full Text] [Related]
31. Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics.
Chen F; Alphonse M; Liu Q
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 May; 12(3):e1609. PubMed ID: 31797562
[TBL] [Abstract][Full Text] [Related]
32. Viral Vectors for the
Asmamaw Mengstie M
Front Bioeng Biotechnol; 2022; 10():895713. PubMed ID: 35646852
[TBL] [Abstract][Full Text] [Related]
33. Applications and developments of gene therapy drug delivery systems for genetic diseases.
Pan X; Veroniaina H; Su N; Sha K; Jiang F; Wu Z; Qi X
Asian J Pharm Sci; 2021 Nov; 16(6):687-703. PubMed ID: 35027949
[TBL] [Abstract][Full Text] [Related]
34. Nanoparticle-mediated interleukin-12 cancer gene therapy.
Hallaj-Nezhadi S; Lotfipour F; Dass C
J Pharm Pharm Sci; 2010; 13(3):472-85. PubMed ID: 21092717
[TBL] [Abstract][Full Text] [Related]
35. Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field.
He ZY; Men K; Qin Z; Yang Y; Xu T; Wei YQ
Sci China Life Sci; 2017 May; 60(5):458-467. PubMed ID: 28527117
[TBL] [Abstract][Full Text] [Related]
36. Clinical applications of the CRISPR/Cas9 genome-editing system: Delivery options and challenges in precision medicine.
Khoshandam M; Soltaninejad H; Mousazadeh M; Hamidieh AA; Hosseinkhani S
Genes Dis; 2024 Jan; 11(1):268-282. PubMed ID: 37588217
[TBL] [Abstract][Full Text] [Related]
37. Non-Viral Delivery System and Targeted Bone Disease Therapy.
Qadir A; Gao Y; Suryaji P; Tian Y; Lin X; Dang K; Jiang S; Li Y; Miao Z; Qian A
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30699924
[TBL] [Abstract][Full Text] [Related]
38. Recent advances in nonviral vectors for gene delivery.
Guo X; Huang L
Acc Chem Res; 2012 Jul; 45(7):971-9. PubMed ID: 21870813
[TBL] [Abstract][Full Text] [Related]
39. An overview of current delivery systems in cancer gene therapy.
El-Aneed A
J Control Release; 2004 Jan; 94(1):1-14. PubMed ID: 14684267
[TBL] [Abstract][Full Text] [Related]
40. Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Alkhaleefah FK; Rahmani AH; Khan AA
Cancer Commun (Lond); 2022 Dec; 42(12):1257-1287. PubMed ID: 36209487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
